Protocols · Metabolism/Weight Loss
Tirz Metabolic Optimization Protocol
Dual GIP/GLP-1 Receptor Agonist | Type 2 Diabetes & Weight Loss
Typical Dose
10–15 mg weekly
After titration from 2.5 mg starter dose
Route
Subcutaneous
Abdomen, thigh, or upper arm — rotate sites
Cycle
9–12 months
Stepped titration with maintenance phase
Storage
Refrigerated 2–8°C
Protect from light; stable at room temp up to 21 days post-reconstitution
Patient version available. Share ?view=patient with patients for the plain-language handout.
Overview
The Tirz Metabolic Optimization Protocol is designed for adult patients with type 2 diabetes mellitus (T2DM), prediabetes with metabolic syndrome features, or obesity (BMI ≥30, or ≥27 with weight-related comorbidities) who require simultaneous glycemic control and meaningful reduction in adiposity. Tirz is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, and its combined incretin activity produces greater A1C reduction and weight loss than selective GLP-1 monotherapy in head-to-head trials (SURPASS-2, SURMOUNT-1).
This protocol uses a stepped titration across 10 mg, 15 mg, and 30 mg strengths to achieve the dual goals of A1C normalization and 15–25% total body weight reduction over 9–12 months, while minimizing the GI adverse event burden that drives discontinuation. The 30 mg strength is used selectively in patients who plateau at 15 mg and remain above metabolic targets; this dose exceeds the FDA-approved maximum (15 mg) and is administered only under observational research framework with informed consent.
Target patient profile: insulin-resistant phenotype, central adiposity, elevated fasting insulin/HOMA-IR, hepatic steatosis, or suboptimal response to metformin ± SGLT2i. The stack is intended to address insulin sensitivity, postprandial glucose excursions, satiety signaling, gastric emptying, and visceral fat reduction in parallel.
Key Benefits
Produces 15–22% mean weight loss and 1.5–2.5% HbA1c reduction over 9–12 months. Superior to selective GLP-1 agonists for both glycemic control and adiposity reduction.
Mechanism of Action
Dual agonist at GIP and GLP-1 receptors. Enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and acts centrally to reduce appetite and food reward signaling.
Molecular Information
Weight
4813.5 Da
Length
39 amino acids
Type
Dual GIP/GLP-1 receptor agonist
Amino Acid Sequence
YXEGTFTSDYSIXLDKIAQKAFVQWLIAGGPSSGAPPPS (X = aminoisobutyric acid; C20 fatty diacid via γGlu-2xAEEA linker at Lys20)
* Synthetic peptide with C20 fatty acid moiety for albumin binding and extended half-life
Pharmacokinetics
Research Indications
Weight Loss / ObesityMOST EFFECTIVE
Mean Reduction
20.9% body weight loss at 15 mg over 72 weeks (SURMOUNT-1)
Visceral Fat
Significant reduction in visceral and ectopic adipose depots
Satiety
Centrally mediated appetite suppression and reduced food reward signaling
Type 2 DiabetesMOST EFFECTIVE
Glycemic Control
HbA1c reduction of 1.5–2.5%; many achieve <6.5%
Insulin Sensitivity
Improved HOMA-IR and hepatic insulin sensitivity
Postprandial Glucose
Blunted excursions via delayed gastric emptying and glucose-dependent insulin release
MASLD/MASHEMERGING
Hepatic Steatosis
Measurable reduction in liver fat and improved transaminases (SYNERGY-NASH)
Fibrosis
Early evidence of fibrosis improvement in MASH cohorts
Cardiometabolic RiskEFFECTIVE
Blood Pressure
Modest systolic BP reduction of 5–8 mmHg
Lipids
Improvements in triglycerides and atherogenic lipid fractions
Inflammation
Reduction in hsCRP and systemic inflammatory markers
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Initiation | 2.5 mg | Weekly × 4 weeks | Subcutaneous |
| Titration Step 2 | 5 mg | Weekly × 4 weeks | Subcutaneous |
| Titration Step 3 | 7.5 mg | Weekly × 4 weeks | Subcutaneous |
| Maintenance (Standard) | 10 mg | Weekly | Subcutaneous |
| Optimization | 15 mg | Weekly | Subcutaneous |
| Plateau (Investigational) | 30 mg | Weekly | Subcutaneous |
| Long-term Maintenance | 10–15 mg | Weekly | Subcutaneous |
Timing · Administer on the same day each week, at any time of day, with or without food. Advance dose only after minimum 4 weeks at current strength and acceptable GI tolerance. Hold pre-procedure per ASA guidance.
Peptide Interactions
- Insulin— Reduce basal insulin 20% on initiation; hypoglycemia riskMONITOR
- Sulfonylureas— Down-titrate or discontinue to avoid hypoglycemiaMONITOR
- SGLT2 Inhibitors— Complementary metabolic effects; monitor volume statusSYNERGISTIC
- Metformin— Standard background therapy; no dose adjustment neededCOMPATIBLE
- Sema— Do not combine GLP-1 agonists; switch rather than stackAVOID
- Reta— Class duplication; do not co-administer incretin agonistsAVOID
- BPC-157— May mitigate GI side effects during titrationSYNERGISTIC
- CJC-1295/Ipamorelin— May help preserve lean mass during rapid weight lossSYNERGISTIC
- Tesofensine— Additive appetite suppression; risk of excessive caloric deficitMONITOR
How to Reconstitute
- 1
Wash hands and prepare clean work surface with alcohol swabs, bacteriostatic water, syringes, and sealed peptide vial.
- 2
Allow lyophilized vial to reach room temperature for 15–20 minutes before reconstitution.
- 3
Wipe rubber stoppers of both peptide vial and bacteriostatic water vial with alcohol swab; allow to air dry.
- 4
Draw appropriate volume of bacteriostatic water into syringe (typically 2 mL for standard reconstitution of 10–30 mg vial).
- 5
Insert needle into peptide vial at an angle and slowly trickle water down the inner wall — do not spray directly onto powder.
- 6
Remove syringe and gently swirl vial to dissolve. Do not shake — agitation can denature the peptide.
- 7
Allow 2–3 minutes for full dissolution. Solution should appear clear and colorless.
- 8
Calculate dose volume based on vial concentration (e.g., 10 mg in 2 mL = 5 mg/mL → 2 mg dose = 0.4 mL).
- 9
Draw target dose into insulin syringe; tap to dislodge bubbles and expel air.
- 10
Clean injection site with alcohol swab; inject subcutaneously at 90° into abdomen, thigh, or upper arm.
- 11
Label vial with reconstitution date; store reconstituted product refrigerated at 2–8°C.
- 12
Use reconstituted vial within 21–28 days; discard if cloudy, discolored, or particulate matter develops.
Quality Indicators
Clear, Colorless Solution
Properly reconstituted Tirz appears as a clear, colorless solution with no visible particles.
Complete Dissolution
Powder fully dissolves within 2–3 minutes of gentle swirling without need for shaking.
Slight Foaming
Minor foaming on reconstitution is acceptable; allow to settle before drawing dose.
Cloudiness or Particulates
Discard vial — indicates contamination, degradation, or incompatible diluent.
Yellow/Brown Discoloration
Indicates oxidation or degradation; do not administer.
What to Expect
Week 1–2: Reduced appetite, smaller portion sizes, mild nausea peaking within 48 hours of injection
Week 4: 2–4% body weight reduction, HbA1c down 0.3–0.7%, GI symptoms attenuating
Week 8: 4–7% weight loss, improved fasting glucose, modest BP and triglyceride improvements
Week 12: 7–10% weight loss, HbA1c down 1.0–1.8%, measurable waist circumference reduction
Month 6: 12–18% weight loss on 15 mg, HbA1c often near target, visceral fat reduction
Month 9–12: Cumulative 15–22% weight loss; many prediabetics revert to normoglycemia
GI side effects (nausea, constipation, eructation) are dose-dependent and typically transient
Lean mass loss of 20–30% of total weight loss expected without protein + resistance training intervention
10–15% of patients are low responders (<5% weight loss at 6 months) — reassess adherence and concurrent medications
Side Effects & Safety
- Nausea, vomiting, diarrhea, or constipation (most common; dose-dependent, usually transient)
- Early satiety, dyspepsia, eructation ("sulfur burps")
- Injection site reactions (erythema, pruritus)
- Hypoglycemia when combined with insulin or sulfonylureas
- Gallbladder events (cholelithiasis, cholecystitis) with rapid weight loss
- Sarcopenia and loss of lean mass without protein/resistance training
- Dehydration with risk of acute kidney injury, particularly in elderly
When to Stop & Call Provider
- Persistent severe abdominal pain radiating to back (possible pancreatitis)
- Neck mass, hoarseness, or persistent dysphagia (thyroid C-cell concern)
- Severe vomiting with inability to maintain hydration
- Signs of allergic reaction (rash, swelling, dyspnea)
- Vision changes (possible diabetic retinopathy progression)
- Lipase >3× ULN with symptoms
References
SURMOUNT-1: Tirzepatide Once Weekly for the Treatment of Obesity
Landmark RCT demonstrating 20.9% mean weight reduction at 15 mg dose over 72 weeks in adults with obesity without diabetes. Established Tirz as the most effective pharmacologic weight loss agent to date.
SURPASS-2: Tirzepatide versus Semaglutide Once Weekly in T2DM
Direct comparison versus semaglutide 1 mg showed superior HbA1c reduction (2.3% vs 1.9%) and weight loss (11.2 kg vs 5.7 kg at 15 mg) in patients with type 2 diabetes.
SURPASS-1 through SURPASS-5: Tirzepatide for Type 2 Diabetes
Comprehensive phase 3 program demonstrating HbA1c reductions of 1.8–2.6% across monotherapy and add-on therapy contexts, supporting FDA approval of Mounjaro for T2DM.
SYNERGY-NASH: Tirzepatide for MASH with Fibrosis
Phase 2 trial showing significant MASH resolution and fibrosis improvement with tirzepatide at 5, 10, and 15 mg doses over 52 weeks, supporting emerging hepatology indication.
SURMOUNT-2: Tirzepatide for Obesity in Type 2 Diabetes
Demonstrated 15.7% mean weight reduction at 15 mg in patients with both obesity and T2DM, addressing the historically blunted weight loss response in diabetic populations.